IL-36RN Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, IF, E |
---|---|
Primary Accession | Q9UBH0 |
Other Accession | NP_775262, 27894310 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 17 kDa Observed: 27 kDa |
Application Notes | IL-36RN antibody can be used for detection of IL-36RN by Western blot at 1 - 2 µg/ml. |
Gene ID | 26525 |
---|---|
Target/Specificity | IL36RN; IL-36RN antibody is human specific. At least two isoforms of IL-36RN are known to exist |
Reconstitution & Storage | IL-36RN antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
Precautions | IL-36RN Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | IL36RN (HGNC:15561) |
---|---|
Function | Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. May activate an anti- inflammatory signaling pathway by recruiting SIGIRR. |
Cellular Location | Cytoplasm. Secreted. Note=The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10; it results in protein translocation from the cytoplasm into the ERGIC (endoplasmic reticulum-Golgi intermediate compartment) followed by vesicle entry and secretion. |
Tissue Location | Predominantly expressed in skin keratinocytes but not in fibroblasts, endothelial cells or melanocytes. Detected also in the spleen, brain leukocyte and macrophage cell types. Increased in lesional psoriasis skin. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IL-36RN is is a member of the interleukin 1 cytokine family whose gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2 (1). IL-36RN specifically inhibits the activation of NF-kappaB induced IL-36A (2). The opposing activities of these cytokines have been suggested to be involved in the regulation of skin inflammation (3). Like the IL-36 cytokines (IL-36A, IL-36B and IL-36G), IL-36RN requires post-translational processing for full agonist activity, but the cleavage mechanism is currently unknown (4).
References
Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 2000; 275:1169-75.
Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 2001; 167:1440-6.
Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 2007; 204:2603-14.
Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist agonist (IL-36a, IL-36b, and IL-36g) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011; 286:42594-602.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.